6533b861fe1ef96bd12c592c
RESEARCH PRODUCT
Intratumoral Heterogeneity, Its Contribution to Therapy Resistance and Methodological Caveats to Assessment
Mirjam RenovanzElla L. Kimsubject
cancer stem cellsCancer Researchmedicine.medical_specialtytumor clones selectionEarly detectionintratumor heterogeneityBioinformaticslcsh:RC254-282Intratumor heterogeneityCancer stem cellmedicinecancerTreatment resistanceIntensive care medicineCancer preventionbusiness.industryintratumor spatiotemporal patternsCancerOpinion Articlelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetumor recurrenceCancer treatmentTumor recurrenceOncologybusinessanti-cancer therapydescription
Cancer is one of the most urgent health issues of today. According to WHO, the number of cancer cases is expected to increase by 75% in the next two decades (1). Despite some remarkable achievements in the fields of cancer prevention and early detection, the goal of developing effective anti-cancer therapies still remains unmet. Tumor recurrence due to treatment resistance is the most common cause of death from cancer. Delineating cellular and molecular mechanisms underlying tumor recurrence is of prime importance for the ability to improve the efficacy of existing therapies and develop new strategies to cancer treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-06-10 | Frontiers in Oncology |